Key Points
- CFO James Budge sold 11,006 Hinge Health shares on March 23 at an average price of $42.26 for a total of $465,113.56, leaving him with 401,427 shares (a 2.67% reduction) valued at about $16.96 million.
- Hinge Health posted a strong quarter on Feb. 10 with $0.49 EPS versus $0.04 expected and revenue of $170.73 million, up 45.5% year‑over‑year.
- The stock has a market capitalization of $3.16 billion and a negative PE (-3.13), a 52‑week range of $30.08–$62.18, and an average analyst consensus of "Moderate Buy" with a $57.07 average price target.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CFO James Budge sold 11,006 shares of Hinge Health stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $42.26, for a total value of $465,113.56. Following the sale, the chief financial officer directly owned 401,427 shares of the company's stock, valued at $16,964,305.02. This represents a 2.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Hinge Health Stock Performance
HNGE stock opened at $40.08 on Thursday. The company's 50-day simple moving average is $40.78 and its 200 day simple moving average is $46.42. Hinge Health Inc. has a 52 week low of $30.08 and a 52 week high of $62.18. The company has a market capitalization of $3.16 billion and a PE ratio of -3.13.
Hinge Health (NYSE:HNGE - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.45. The business had revenue of $170.73 million for the quarter, compared to the consensus estimate of $157.31 million. The firm's revenue for the quarter was up 45.5% compared to the same quarter last year.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on HNGE. Wall Street Zen upgraded shares of Hinge Health from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Citizens Jmp reissued a "market outperform" rating and set a $65.00 price target on shares of Hinge Health in a research report on Wednesday, February 11th. Barclays lowered their price objective on Hinge Health from $60.00 to $52.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 11th. Stifel Nicolaus set a $59.00 price objective on Hinge Health in a report on Thursday, February 5th. Finally, Canaccord Genuity Group reduced their target price on Hinge Health from $65.00 to $53.00 and set a "buy" rating on the stock in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $57.07.
Read Our Latest Analysis on Hinge Health
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. acquired a new position in Hinge Health during the second quarter worth about $71,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Hinge Health in the 2nd quarter valued at approximately $966,000. JPMorgan Chase & Co. bought a new stake in shares of Hinge Health during the 2nd quarter valued at approximately $43,840,000. Legal & General Group Plc bought a new stake in shares of Hinge Health during the 2nd quarter valued at approximately $1,445,000. Finally, Franklin Resources Inc. acquired a new position in Hinge Health during the 2nd quarter worth approximately $28,462,000.
About Hinge Health
(
Get Free Report)
Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.
Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
